• Explore /
  • Poster
  • / LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma.

LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma.

Abstract Poster

Authors

null

Jong-Mu Sun

Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Jong-Mu Sun , Peter C. Enzinger , Antoine Adenis , Manish A. Shah , Ken Kato , Jaafar Bennouna , Toshihiko Doi , Natalyn Nicole Hawk , Li Yu , Sukrut Shah , Pooja Bhagia , Lin Shen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04949256

DOI

10.1200/JCO.2022.40.4_suppl.TPS367

Abstract #

TPS367

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jong-Mu Sun

First Author: Deirdre Jill Cohen

First Author: Patricio Eduardo Yanez

First Author: Zev A. Wainberg